Skip to main content
. Author manuscript; available in PMC: 2021 Mar 11.
Published in final edited form as: Cell Rep. 2021 Feb 16;34(7):108751. doi: 10.1016/j.celrep.2021.108751

Figure 3. Haploid Kmt2c deletion conveys a selective advantage to HSCs that divide after chemotherapy.

Figure 3.

(A) Overview of the experiment. Arrows indicated treatment days for pIpC, CY, and 5-FU.

(B) HSC numbers in Fgd5-CreER; Kmt2cflox/+ mice after 1 or 3 cycles of the indicated treatments. n = 4–8.

(C and D) Percentage of HSCs with Kmt2c deletions after 1 or 3 cycles of the indicated treatments. n = 5–9.

(E) Percentage of ZsGreen-positive HSCs, among all CD150+CD48−LSK cells, after the indicated treatments. n = 4–6. Error bars reflect standard deviation. **p <0.01, ***p < 0.001; comparisons were made by one-way ANOVA with Holm-Sidak post hoc test.